QuidelOrtho (QDEL)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$13.97+0.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
Broken: Primary pillar broken — Revenue at or above $2.7 billion in FY26: FY26 revenue guidance $2.52B-$2.60B vs $2.7B target.
QuidelOrtho aims to improve profit margins and cash flow in 2026. Revenue guidance was raised to about $2.725 billion. The company is growing through new products and acquisitions. A new CFO was hired to strengthen financial discipline.
Revenue fell 10.5% year over year in the latest quarter. Profit margins dropped from 23.1% to 17.5%. Regulatory and geopolitical problems hurt sales in China and the Middle East. The company is still losing money and faces tough market conditions.
The market expects about 2% revenue growth next year. Our fair value is much higher than the Street median, reflecting optimism on recovery. We see risk in margin and cash flow targets given recent declines.
Breaks if: Margin falls below 17.5% in FY26
Focus on expanding adjusted EBITDA margin and improving cash flow through operational execution and cost actions in 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on recovery. The current thesis state indicates a cautious watch as the company navigates challenges while showing some positive revenue growth through innovation and acquisitions.
The market currently prices QDEL as a company that is cheap compared to its peers, with a notable expectations gap. This suggests that investors may not be fully accounting for the potential recovery in financial performance.
Management is focused on expanding margins and improving cash flow, but recent results show mixed delivery. The company has faced challenges in cash flow, while revenue growth in key segments indicates some positive momentum.
The future performance of QDEL hinges on its ability to raise guidance in the next quarter and navigate external pressures, such as geopolitical issues and sector performance. Additionally, the impact of broader economic conditions, like job growth, will be crucial.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The company cut its 2026 revenue outlook. This indicates potential regulatory and geopolitical challenges. Analysts also lowered growth expectations. This impacts product innovation goals for the company.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA margin declined from 22% in 2025-Q4 to 17.5% in 2026-Q1 but improved to 20.5% in 2026-Q2. Free cash flow guidance was withdrawn in 2026-Q2 after prior positive guidance. Management continues to emphasize margin expansion and cash flow improvement, showing mixed delivery with recent margin recovery but cash flow challenges.
“We remain focused on ... margin expansion, cash flow improvement ... strengthening our balance sheet.”
“We are well positioned to deliver on our objectives to expand our adjusted EBITDA margin and improve cash flow in 2026.”
“Cost-savings initiatives drove meaningful margin expansion ... well positioned to generate substantially stronger free cash flow in 2026.”
Breaks if: Revenue decline in Labs segment exceeds 5% in FY26
Breaks if: CFO transition causes financial or operational disruption
Breaks if: Free cash flow falls below $100 million in FY26
Focus on expanding adjusted EBITDA margin and improving cash flow through operational execution and cost actions in 2026.
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA margin declined from 22% in 2025-Q4 to 17.5% in 2026-Q1 but improved to 20.5% in 2026-Q2. Free cash flow guidance was withdrawn in 2026-Q2 after prior positive guidance. Management continues to emphasize margin expansion and cash flow improvement, showing mixed delivery with recent margin recovery but cash flow challenges.
“We remain focused on ... margin expansion, cash flow improvement ... strengthening our balance sheet.”
“We are well positioned to deliver on our objectives to expand our adjusted EBITDA margin and improve cash flow in 2026.”
“Cost-savings initiatives drove meaningful margin expansion ... well positioned to generate substantially stronger free cash flow in 2026.”
Breaks if: Revenue falls below $2.7 billion in FY26
Over the next 1 to 3 years, QDEL's performance will depend on its execution of management priorities and external market conditions. Not investment advice.